PT  - JOURNAL ARTICLE
AU  - Murray, Conor H.
AU  - Gannon, Brenda M.
AU  - Winsauer, Peter J.
AU  - Cooper, Ziva D.
AU  - Delatte, Marcus S.
ED  - Banks, Matthew
TI  - The Development of Cannabinoids as Therapeutic Agents in the United States
AID  - 10.1124/pharmrev.123.001121
DP  - 2024 Sep 01
TA  - Pharmacological Reviews
PG  - 915--955
VI  - 76
IP  - 5
4099  - http://pharmrev.aspetjournals.org/content/76/5/915.short
4100  - http://pharmrev.aspetjournals.org/content/76/5/915.full
SO  - Pharmacol Rev2024 Sep 01; 76
AB  - Cannabis is one of the oldest and widely used substances in the world. Cannabinoids within the cannabis plant, known as phytocannabinoids, mediate cannabis’ effects through interactions with the body’s endogenous cannabinoid system. This endogenous system, the endocannabinoid system, has important roles in physical and mental health. These roles point to the potential to develop cannabinoids as therapeutic agents while underscoring the risks related to interfering with the endogenous system during nonmedical use. This scoping narrative review synthesizes the current evidence for both the therapeutic and adverse effects of the major (i.e., Δ9-tetrahydrocannabinol and cannabidiol) and lesser studied minor phytocannabinoids, from nonclinical to clinical research. We pay particular attention to the areas where evidence is well established, including analgesic effects after acute exposures and neurocognitive risks after acute and chronic use. In addition, drug development considerations for cannabinoids as therapeutic agents within the United States are reviewed. The proposed clinical study design considerations encourage methodological standards for greater scientific rigor and reproducibility to ultimately extend our knowledge of the risks and benefits of cannabinoids for patients and providers.Significance Statement This work provides a review of prior research related to phytocannabinoids, including therapeutic potential and known risks in the context of drug development within the United States. We also provide study design considerations for future cannabinoid drug development.